What is Microdermics?
Microdermics is at the forefront of transforming drug delivery for the biopharmaceutical industry and patients. The company has developed a proprietary microneedle injection system designed to replace traditional hypodermic needles, addressing a critical need in the vast $800 billion global biotherapeutics market. Their scalable, customizable, and versatile microneedle platform is engineered to enhance patient comfort and optimize drug delivery efficiency, targeting biopharma companies and patients seeking advanced administration solutions.
How much funding has Microdermics raised?
Microdermics has raised a total of $1M across 1 funding round:
Unspecified
$1M
Unspecified (2017): $1M with participation from K5 Ventures and Shoreline Ventures
Key Investors in Microdermics
K5 Ventures
K5 Ventures is an early-stage venture capital fund based in California, known for accelerating game-changing innovations and backing exceptional products and teams, particularly those leveraging artificial intelligence.
Shoreline Ventures
Shoreline Venture Management LLC is a venture capital firm with offices in Vancouver and San Francisco, specializing in early-stage tech startups and investing in sectors like enterprise software, healthcare IT, and big data analytics.
What's next for Microdermics?
The recent major strategic investment signals a pivotal growth phase for Microdermics. This capital infusion is expected to accelerate the company's market penetration and further development of its innovative microneedle technology. With a focus on enhancing patient experience and drug efficacy, Microdermics is well-positioned to capture a significant share of the biotherapeutics market, driving forward advancements in drug administration.
See full Microdermics company page
